Verastem Poised for Breakout with Imminent FDA Approval
AI Prediction of Verastem, Inc. (VSTM)
Verastem, a biopharmaceutical company, is on the cusp of potentially transformative growth with its focus on RAS/MAPK pathway-driven cancers. The upcoming catalysts, including the possible FDA approval of its leading drug candidates avutometinib and defactinib for low-grade serous ovarian cancer, could significantly impact its market valuation and operational dynamics. Considering the strategic alignment with industry requirements and the anticipation surrounding its clinical results, Verastem presents a compelling investment opportunity with considerable upside potential.
VSTM Report Information
Prediction Date2025-07-03
Close @ Prediction$4.80
Mkt Cap326m
IPO DateN/a
AI-derived Information
Recent News for VSTM
- Jun 3, 8:10 pm — VSTM Stock Climbs After-Hours As FDA Grants Fast Track To Lung Cancer Drug Retail Eyes The Next Keytruda (Stocktwits)
- May 27, 7:30 am — Verastem Oncology to Present at Jefferies Healthcare Conference (Business Wire)
- May 26, 7:30 am — Verastem Oncology Appoints Michael P. Bailey to its Board of Directors (Business Wire)
- May 12, 7:30 am — Verastem Oncology to Present at Upcoming Investor Conferences (Business Wire)
- May 8, 7:30 am — On World Ovarian Cancer Day, LGSOC Resource Guide Launches to Support People Living with Low-Grade Serous Ovarian Cancer (Business Wire)
- May 7, 5:16 pm — Verastem: Q1 Earnings Snapshot (Associated Press)
- May 7, 4:01 pm — Verastem Oncology Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates (Business Wire)
- Apr 30, 7:30 am — Verastem Oncology Launches HCP and Patient Reimagine Campaign to Increase Awareness of AVMAPKI FAKZYNJA CO-PACK for KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer (Business Wire)
- Apr 23, 7:30 am — Verastem Oncology to Report First Quarter 2026 Financial Results on May 7, 2026 (Business Wire)
- Apr 10, 7:00 am — Verastem Oncology Announces Two-Year Median Follow-Up Data on AVMAPKI FAKZYNJA Combination Therapy (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian Cancer at the SGO 2026 Annual Meeting on Womens Cancers (Business Wire)
- Apr 2, 4:05 pm — Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
- Mar 17, 6:03 pm — Verastem Oncology Announces Late Breaking and Regular Abstracts Accepted for Presentation at the AACR Annual Meeting 2026 (Business Wire)
Welcome to ScanScor. What you're reading is no ordinary summary -- it's the result of a carefully-crafted interactive session with OpenAI's most advanced models crafted from news, trial details, and financial data. This report attempts to maximize the potential for OpenAI's smartest GPT-based analysis engine, guided by tightly structured prompts to expose the forces behind today's market movers and to predict the future.
Disclaimer: This report is for informational purposes only. It does not constitute financial advice. Always do your own research before making any investment.